Scarica l'app Stockscreener
46.96
0.76%
-0.36
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Precedente Chiudi:
$47.32
Aprire:
$47.03
Volume 24 ore:
4.28M
Relative Volume:
2.55
Capitalizzazione di mercato:
$5.97B
Reddito:
$947.36M
Utile/perdita netta:
$392.47M
Rapporto P/E:
24.98
EPS:
1.88
Flusso di cassa netto:
$392.71M
1 W Prestazione:
-2.17%
1M Prestazione:
+2.62%
6M Prestazione:
-7.67%
1 anno Prestazione:
+29.08%
Intervallo 1D:
$46.88
$48.20
Intervallo di 1 settimana:
$46.45
$49.60
Portata 52W:
$33.15
$65.53
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Nome
Halozyme Therapeutics Inc
Settore
Industria
Telefono
(858) 794-8889
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Confronta HALO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
46.96 | 5.97B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Iniziato | TD Cowen | Outperform |
| 2023-07-24 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Berenberg | Buy |
| 2023-03-16 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Ripresa | Morgan Stanley | Overweight |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Iniziato | Evercore ISI | Outperform |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Reiterato | The Benchmark Company | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | The Benchmark Company | Buy |
| 2020-02-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Buy |
| 2019-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Ripresa | Piper Jaffray | Neutral |
| 2018-05-11 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2017-10-16 | Reiterato | Piper Jaffray | Overweight |
| 2017-01-06 | Downgrade | Citigroup | Buy → Neutral |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-11-18 | Iniziato | Citigroup | Buy |
| 2015-09-22 | Iniziato | Barclays | Overweight |
| 2015-06-22 | Reiterato | JP Morgan | Overweight |
| 2015-03-03 | Reiterato | UBS | Buy |
| 2015-02-18 | Reiterato | MLV & Co | Buy |
| 2015-01-08 | Reiterato | MLV & Co | Buy |
Mostra tutto
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Raised by Tidal Investments LLC - MarketBeat
Sanctuary Advisors LLC Purchases 16,511 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Brokerages Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $61.11 - MarketBeat
Halozyme Therapeutics' (HALO) Buy Rating Reiterated at HC Wainwright - MarketBeat
Wellington Management Group LLP Has $3.73 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
9 Analysts Have This To Say About Halozyme Therapeutics - Benzinga
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - MSN
Johnson & Johnson Rybrevant version rejected in US (JNJ:NYSE) - Seeking Alpha
Needle Free Drug Delivery Devices Market Industry Trends and Forecasts to 2035, Featuring Profiles of Halozyme, HNS, INOVIO Pharmaceuticals and Medical International Technology and PharmaJet - Yahoo Finance
How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08% - Yahoo Finance
Geode Capital Management LLC Purchases 30,901 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Retirement Systems of Alabama Purchases 74,173 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Trading (HALO) With Integrated Risk Controls - Stock Traders Daily
57,526 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by World Investment Advisors LLC - MarketBeat
Zacks Research Issues Optimistic Forecast for HALO Earnings - MarketBeat
Halozyme to Present at Upcoming Investor Conferences - The Eastern Progress Online
Q1 EPS Forecast for Halozyme Therapeutics Boosted by Analyst - MarketBeat
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer - The Eastern Progress Online
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock - MSN
Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now? - Yahoo Finance
Hodges Capital Management Inc. Trims Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Pier Capital LLC - MarketBeat
Castleark Management LLC Takes $3.99 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Janus Henderson Group PLC Purchases 31,871 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now - Yahoo Finance
HALO vs. FOLD: Which Stock Is the Better Value Option? - Yahoo Finance
Is Halozyme Therapeutics (HALO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Exploring Three High Growth Tech Stocks in the United States - Yahoo Finance
Erste Asset Management GmbH Invests $2.72 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
94,009 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by Caisse DE Depot ET Placement DU Quebec - MarketBeat
Bridgewater Associates LP Has $659,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Phase 2 Data in Advanced Pancreas Cancer Featured in an Oral Presentation at ASCO - Marketscreener.com
Edgestream Partners L.P. Purchases 46,352 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Hantz Financial Services Inc. Invests $9.26 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
CreativeOne Wealth LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
San Diego’s Halozyme withdraws $2.1B Evotec bid, just one week after making offer - MSN
Halozyme abandons Evotec bid - Speciality Chemicals Magazine
Townsquare Capital LLC Boosts Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
Glenmede Trust Co. NA Acquires 109,283 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Seems To Use Debt Rather Sparingly - Simply Wall St
Fisher Asset Management LLC Has $18.55 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
RPg Family Wealth Advisory LLC Purchases New Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Swedbank AB Lowers Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Charles Schwab Investment Management Inc. - MarketBeat
Halozyme CEO and CFO to Present at Major Healthcare Investor Conferences in December - StockTitan
Halozyme: Growth Amid Uncertainty After Failed Acquisition (Rating Downgrade) (HALO) - Seeking Alpha
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up - MSN
Halozyme abandons its €2bn pursuit of Evotec - pharmaphorum
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Intech Investment Management LLC - MarketBeat
Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Halozyme Therapeutics Inc Azioni (HALO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Oct 15 '24 |
Option Exercise |
18.15 |
10,000 |
181,455 |
183,756 |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Oct 15 '24 |
Sale |
53.75 |
10,000 |
537,469 |
173,756 |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Oct 16 '24 |
Sale |
53.26 |
10,000 |
532,590 |
173,756 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):